Hunan Er Kang Pharmaceutical (300267) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hunan Er Kang Pharmaceutical stock ¥0.39, price ¥2.94, that is 86.7% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range ¥2.06 – ¥5.11 · fair‑value band ¥0.3800 – ¥0.4000 · the ¥2.94 price screens above the ¥0.3900 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Hunan Er Kang Pharmaceutical in your weekly email
Every Wednesday you see whether Hunan Er Kang Pharmaceutical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally.
Show moreShow less
The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol.
It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets.
In addition, the company offers conventional pharmaceutical excipients include pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose; and new pharmaceutical excipients comprise hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate products.
Hunan Er-Kang Pharmaceutical Co., Ltd was founded in 2003 and is based in Changsha, China.
Stock analysis
Hunan Er Kang Pharmaceutical (300267) currently trades at ¥2.94, while our model-based Fair Value estimate is ¥0.3900, 87% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ¥0.8800 per share, and 0 of the 13 models we run sit above the ¥2.94 price.
Bear case: the Multiples group reads lowest at ¥0.2200, and 13 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: ¥0.3800 (bear) to ¥0.4000 (bull), the price of ¥2.94 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Hunan Er Kang Pharmaceutical reported revenue of 1.2B CNY in FY2025 versus 2.2B CNY in FY2021, a compound −15.0%/yr. Reported net income was −380M CNY in FY2025.
Key figures
Market cap 6.1B CNY (≈ $910M) Small · P/S ratio 5.43 · EPS (TTM) ¥−0.1800 · Dividend yield 0.2% · Net margin −35.5% · Return on equity −9.4% · Return on assets (EBIT) −5.1% (5-year average) · Operating margin 9.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).
What moves the price
The share trades about 39% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −87%, 300267 screens richer than that median.
Fair Value models
Bear¥0.3800Fair Value ¥0.3900Bull¥0.4000
Price ¥2.94 · Downside -86.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+2.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.3%
Start year 2020 (pandemic). Over 10 years: −4.0% a year
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.6% (2019) → −32.5% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+34.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +31.9% a year for the price.
Compare Hunan Er Kang Pharmaceutical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−86.7% · Bottom 25%
Profitability
Return on assets−7.8% · Bottom 25%
Net margin (12 months)−35.5% · Bottom 25%
Operating margin (12 months)9.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−2.5% · Below median
Dividend yield (12 months)0.2% · Bottom 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hunan Er Kang Pharmaceutical Fair Value". https://www.fairvalue-calculator.com/stock/300267
Frequently asked questions
Is Hunan Er Kang Pharmaceutical (300267) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of ¥0.3900 versus a price of ¥2.94, about 87% lower (overvalued).
What is the fair value of 300267?
Our model-based fair value for Hunan Er Kang Pharmaceutical is ¥0.3900 (as of Nov 5, 2026), built from audited fundamentals. The current price: ¥2.94.
What is the quality score of 300267?
Hunan Er Kang Pharmaceutical has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hunan Er Kang Pharmaceutical (300267)?
Our model-based price target is the fair value of ¥0.3900 (as of Nov 5, 2026) from 13 valuation models. Cautious scenario ¥0.3800, optimistic scenario ¥0.4000. It is a calculation from audited fundamentals, not an analyst target.
What is the Hunan Er Kang Pharmaceutical stock forecast for 2026?
Our models put fair value at ¥0.3900, about 87% lower versus a price of ¥2.94 (overvalued). Cautious scenario ¥0.3800, optimistic scenario ¥0.4000. The calculation is refreshed regularly with new filings.
What is the revenue of Hunan Er Kang Pharmaceutical (300267)?
Hunan Er Kang Pharmaceutical reported trailing-twelve-month revenue of about 1.1B CNY (latest available figure, as of Nov 5, 2026).
Does Hunan Er Kang Pharmaceutical pay a dividend?
Hunan Er Kang Pharmaceutical currently shows a dividend yield of 0.19% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Hunan Er Kang Pharmaceutical (300267)?
Hunan Er Kang Pharmaceutical has a dividend yield of 0.2%.
What growth is priced into Hunan Er Kang Pharmaceutical (300267)?
For today's price to be fair in a discounted-cash-flow model, Hunan Er Kang Pharmaceutical would have to grow free cash flow by +34.1 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -13.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 300267 use?
Our models discount Hunan Er Kang Pharmaceutical at 10.4 %: a base by market capitalisation (small), damped by beta 0.49, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hunan Er Kang Pharmaceutical that is +34.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Hunan Er Kang Pharmaceutical (300267) delivered so far?
Over the past 5 years revenue at Hunan Er Kang Pharmaceutical grew -13.3 % a year. The price currently implies free-cash-flow growth of +34.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hunan Er Kang Pharmaceutical (300267) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Hunan Er Kang Pharmaceutical (+34.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hunan Er Kang Pharmaceutical (300267)?
The free-cash-flow yield on the price is 1.55 %: that much free cash flow Hunan Er Kang Pharmaceutical produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hunan Er Kang Pharmaceutical (300267)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hunan Er Kang Pharmaceutical it is ¥0.3900 per share (as of Nov 5, 2026), against a price of ¥2.94. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Hunan Er Kang Pharmaceutical stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 300267 trades above its calculated fair value: price ¥2.94, fair value ¥0.3900, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300267?
No. The price is what the market pays today (¥2.94); the fair value is what the company's own numbers justify (¥0.3900). For Hunan Er Kang Pharmaceutical the two are ¥2.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hunan Er Kang Pharmaceutical worth?
The market values Hunan Er Kang Pharmaceutical at about 6.1B CNY (market capitalisation, as of Nov 5, 2026). Per share that is ¥2.94; our models calculate a fair value of ¥0.3900 per share.
What do the bullish and bearish scenarios say about 300267?
Our models span a range for Hunan Er Kang Pharmaceutical: cautious scenario ¥0.3800, base ¥0.3900, optimistic ¥0.4000 per share (as of Nov 5, 2026, price ¥2.94). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Hunan Er Kang Pharmaceutical (300267)?
Balance-sheet figures for Hunan Er Kang Pharmaceutical (as of Nov 5, 2026): return on equity −9.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is 300267 from its 52-week high?
Hunan Er Kang Pharmaceutical trades at ¥2.94, about 39% below its 52-week high of ¥4.84 and 6% above the low of ¥2.77 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.3900 is for.
Which stocks are comparable to Hunan Er Kang Pharmaceutical?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hunan Er Kang Pharmaceutical stock attractive at the current price?
The data as of Nov 5, 2026: price ¥2.94, calculated fair value ¥0.3900 (−87%), Quality Score 51/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300267 calculated?
We run Hunan Er Kang Pharmaceutical through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of ¥0.3900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Hunan Er Kang Pharmaceutical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hunan Er Kang Pharmaceutical (300267)?
The closing price on Nov 6, 2026 was ¥2.94. Our model-based fair value is ¥0.3900, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hunan Er Kang Pharmaceutical right now?
The price sits above even our optimistic bull case (¥0.4000). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. The models converge in a tight band (¥0.3800 to ¥0.4000), unusually little disagreement for a valuation.
Key figures of Hunan Er Kang Pharmaceutical
How large is the market capitalisation of Hunan Er Kang Pharmaceutical (300267)?
The market capitalisation of Hunan Er Kang Pharmaceutical is 6.1B CNY (≈ $910M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hunan Er Kang Pharmaceutical (300267)?
The price-to-sales ratio of Hunan Er Kang Pharmaceutical is 5.43 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hunan Er Kang Pharmaceutical (300267)?
Earnings per share at Hunan Er Kang Pharmaceutical are ¥−0.1800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hunan Er Kang Pharmaceutical (300267)?
The dividend yield of Hunan Er Kang Pharmaceutical is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hunan Er Kang Pharmaceutical (300267)?
The net margin of Hunan Er Kang Pharmaceutical is −35.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hunan Er Kang Pharmaceutical (300267)?
The return on equity (ROE) of Hunan Er Kang Pharmaceutical is −9.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hunan Er Kang Pharmaceutical (300267)?
On an EBIT basis the return on assets of Hunan Er Kang Pharmaceutical is −5.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hunan Er Kang Pharmaceutical (300267)?
The operating margin of Hunan Er Kang Pharmaceutical is 9.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hunan Er Kang Pharmaceutical (300267)?
Revenue at Hunan Er Kang Pharmaceutical is growing −2.5% versus a year earlier (3y avg −14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hunan Er Kang Pharmaceutical (300267)?
Earnings per share at Hunan Er Kang Pharmaceutical are growing +229% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Hunan Er Kang Pharmaceutical (300267) hold?
Hunan Er Kang Pharmaceutical holds more cash than debt, 193M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Hunan Er Kang Pharmaceutical in the live analysis
One click puts Hunan Er Kang Pharmaceutical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026